Inclusion Criteria:

* Subject has provided informed consent.
* Subject is ≥ 18 years of age
* Subject is willing and able to comply with all aspects of treatment and evaluation schedule.
* Subject has known CD and a recent history (within last 2 years) of mucosal disease (based on radiologic, endoscopic, or histologic evidence) OR known CD and active disease, based on clinical judgment based on symptoms, laboratory data or other clinical information.

Exclusion Criteria:

* Subject has indeterminate, ulcerative, antibiotic-associated colitis.
* Subject has stool positive for ova and parasite and for Clostridium difficile toxins within 3 months prior to enrollment.
* Subject with other known infectious cause of abdominal symptoms.
* Subject with clinical evidence of renal disease with the past 6 months, defined as estimated glomerular filtration rate (GFR) outside the normal reference range.
* Subject with known history of intestinal obstruction or current obstructive symptoms, such as severe abdominal pain with accompanying nausea or vomiting, based on investigator judgment.
* Subject with a diagnosis of gastroparesis or small bowel or large bowel dysmotility.
* Subject with suspected or known bowel obstruction, stricture (defined as unequivocal proximal upstream dilation equal ≥ 2.5 cm), or fistula.
* Subject has used non-steroidal anti-inflammatory drugs including aspirin, two times per week, during the 4 weeks preceding enrollment. Low dose aspirin regimens (≤ 100 mg daily) are acceptable and not exclusionary.
* Subject suffers from any condition, such as swallowing problems, that precludes compliance with study and/or device instructions.
* Subject with cardiac pacemaker or other implanted electromedical device.
* Subject has an allergy or other known contraindication to the medications used in the study.
* Subject is pregnant (documented by a positive pregnancy test) or is actively breast-feeding.
* Subject is considered to be a part of a vulnerable population (eg. prisoners or those without sufficient mental capacity).
* Subject has a known contraindication to MRE or IC.
* Subject has participated in a drug or device research study within 30 days of enrollment that may interfere with the subject's safety or ability to participate in the study.
* Subject has any medical condition that would make it unsafe for them to participate, per Investigator's discretion
* Subject with ileostomy or colostomy, history of total or subtotal colectomy (including those with ileosigmoidostomy, and ileorectostomy)